IN2012DN00928A - - Google Patents
Info
- Publication number
- IN2012DN00928A IN2012DN00928A IN928DEN2012A IN2012DN00928A IN 2012DN00928 A IN2012DN00928 A IN 2012DN00928A IN 928DEN2012 A IN928DEN2012 A IN 928DEN2012A IN 2012DN00928 A IN2012DN00928 A IN 2012DN00928A
- Authority
- IN
- India
- Prior art keywords
- treatment
- relates
- benzylideneaminoguanidines
- dimethoxybenzylideneamino
- guanidine
- Prior art date
Links
- WNPXUCYRKHVMAD-UHFFFAOYSA-N 2-(benzylideneamino)guanidine Chemical class NC(N)=NN=CC1=CC=CC=C1 WNPXUCYRKHVMAD-UHFFFAOYSA-N 0.000 abstract 1
- FGEWTNKUNGVHKT-UHFFFAOYSA-N 2-[(2-chloro-3,4-dimethoxyphenyl)methylideneamino]guanidine Chemical compound COC1=CC=C(C=NNC(N)=N)C(Cl)=C1OC FGEWTNKUNGVHKT-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0913427A GB0913427D0 (en) | 2009-07-31 | 2009-07-31 | Compounds for treatment of imflammation |
| GBGB1005495.5A GB201005495D0 (en) | 2010-03-31 | 2010-03-31 | Compounds for treatment of inflammation |
| GBGB1010671.4A GB201010671D0 (en) | 2010-06-24 | 2010-06-24 | Compounds for treatment of inflammation |
| PCT/GB2010/001457 WO2011012868A1 (en) | 2009-07-31 | 2010-07-30 | Compounds for treatment of inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN00928A true IN2012DN00928A (ko) | 2015-04-03 |
Family
ID=42799430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN928DEN2012 IN2012DN00928A (ko) | 2009-07-31 | 2010-07-30 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20120190751A1 (ko) |
| EP (1) | EP2470270A1 (ko) |
| JP (1) | JP2013500957A (ko) |
| CN (1) | CN102573993A (ko) |
| AU (1) | AU2010277356A1 (ko) |
| BR (1) | BR112012002267A2 (ko) |
| CA (1) | CA2769541A1 (ko) |
| GB (1) | GB2473095A (ko) |
| IN (1) | IN2012DN00928A (ko) |
| MX (1) | MX2012001144A (ko) |
| NZ (1) | NZ598124A (ko) |
| RU (1) | RU2012106467A (ko) |
| WO (1) | WO2011012868A1 (ko) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3109237A1 (en) * | 2015-06-22 | 2016-12-28 | AnaMar AB | Novel 5-ht2 antagonists |
| CN105561313B (zh) * | 2016-01-25 | 2018-12-25 | 北京大学 | 降低5-ht2br含量和抑制其活性的物质在制备治疗和预防动脉粥样硬化产品中的应用 |
| US11208475B1 (en) * | 2018-01-30 | 2021-12-28 | Flagship Pioneering Innovations V, Inc. | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators |
| US20210177814A1 (en) * | 2018-05-09 | 2021-06-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of guanabenz or derivates thereof for the treatment of type i ifn-dependent pathologies |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69130216T2 (de) * | 1990-03-16 | 1999-03-25 | The Beth Israel Hospital Association, Boston, Mass. | Verwendung von spiperon als immunsuppressivum und antiinflammatorisches mittel |
| US5696128A (en) * | 1994-07-07 | 1997-12-09 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method of regulating immune function |
| EP0711553A1 (en) * | 1994-08-09 | 1996-05-15 | Mario Cagnoni | Use of the Melatonin in the traetment of the articular symptoms of trheumatoid arthritis |
| AU7802700A (en) * | 1999-10-06 | 2001-05-10 | Melacure Therapeutics Ab | Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase |
| GB0019357D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
| US7060711B2 (en) * | 2001-10-25 | 2006-06-13 | Biofrontera Bioscience Gmbh | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist |
| WO2005031000A2 (en) * | 2003-09-25 | 2005-04-07 | Acadia Pharmaceuticals Inc. | Treating neuropathic pain with neuropeptide ff receptor 2 agonists |
| GB0623381D0 (en) * | 2006-11-23 | 2007-01-03 | Acure Pharma Ab | Use of a compound as VEGF inhibitor |
| GB0701170D0 (en) * | 2007-01-22 | 2007-02-28 | Imp Innovations Ltd | Compositions and uses thereof |
| GB0715048D0 (en) * | 2007-08-02 | 2007-09-12 | Glaxo Group Ltd | Novel compounds |
| US20120108668A1 (en) * | 2009-03-24 | 2012-05-03 | Lundstedt Erik Torbjoern | Metabolic profiles |
-
2010
- 2010-07-30 EP EP10739974A patent/EP2470270A1/en not_active Withdrawn
- 2010-07-30 GB GB1012926A patent/GB2473095A/en not_active Withdrawn
- 2010-07-30 RU RU2012106467/15A patent/RU2012106467A/ru not_active Application Discontinuation
- 2010-07-30 AU AU2010277356A patent/AU2010277356A1/en not_active Abandoned
- 2010-07-30 MX MX2012001144A patent/MX2012001144A/es unknown
- 2010-07-30 CA CA2769541A patent/CA2769541A1/en not_active Abandoned
- 2010-07-30 CN CN2010800325573A patent/CN102573993A/zh active Pending
- 2010-07-30 WO PCT/GB2010/001457 patent/WO2011012868A1/en active Application Filing
- 2010-07-30 IN IN928DEN2012 patent/IN2012DN00928A/en unknown
- 2010-07-30 US US13/388,174 patent/US20120190751A1/en not_active Abandoned
- 2010-07-30 JP JP2012522246A patent/JP2013500957A/ja active Pending
- 2010-07-30 BR BR112012002267A patent/BR112012002267A2/pt not_active IP Right Cessation
- 2010-07-30 NZ NZ598124A patent/NZ598124A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB2473095A (en) | 2011-03-02 |
| CN102573993A (zh) | 2012-07-11 |
| GB201012926D0 (en) | 2010-09-15 |
| WO2011012868A1 (en) | 2011-02-03 |
| CA2769541A1 (en) | 2011-02-03 |
| NZ598124A (en) | 2014-01-31 |
| AU2010277356A1 (en) | 2012-03-08 |
| EP2470270A1 (en) | 2012-07-04 |
| RU2012106467A (ru) | 2013-09-10 |
| MX2012001144A (es) | 2012-05-08 |
| JP2013500957A (ja) | 2013-01-10 |
| US20120190751A1 (en) | 2012-07-26 |
| BR112012002267A2 (pt) | 2016-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201491617A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| PH12014501736B1 (en) | Therapeutic use of p75ntr neurotrophin binding protein | |
| MX2009009079A (es) | Anticuerpos anti-il-23p19 de ingenieria. | |
| MX2009009080A (es) | Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica. | |
| MX2011007930A (es) | Conjugados de insulina cristalina. | |
| TN2012000302A1 (en) | Oxyntomodulin peptide analogue | |
| MX351083B (es) | Métodos para el tratamiento de trastornos oncológicos usando cambiadores epimetabólicos, moléculas intracelulares multidimensionales, o influenciadores ambientales. | |
| JO3462B1 (ar) | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها | |
| MX2015009106A (es) | Composiciones de solución sólida y su uso en el tratamiento del dolor intenso. | |
| MX2009009283A (es) | Anticuerpos anti-interleuquina -23r de ingenieria. | |
| MX2009011346A (es) | Tapentadol para tratamiento de dolor con artritis. | |
| MY143269A (en) | Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder | |
| MY155340A (en) | Use of cathepsin c | |
| DK3363437T3 (da) | Aminoindanforbindelser og anvendelse deraf i behandling af smerte | |
| IN2012DN00928A (ko) | ||
| TR200909786A1 (tr) | Sefiksim içeren efervesan tablet ve granül formülasyonu. | |
| HK1141436A1 (en) | Axomadol for treating pain from arthritis | |
| HUE047515T2 (hu) | N-Szubsztituált benzolpropánamidok fájdalom és gyulladás kezelésében történõ alkalmazásra | |
| IL223065A0 (en) | New cathepsin s protease inhibitors, useful in the treatment of e.g. autoimmune disorders, allergy and chronic pain conditions | |
| MY179784A (en) | Use of cathepsin h | |
| WO2011067189A3 (de) | Cmet-inhibitoren zur behandlung der endometriose | |
| UA45304U (ru) | Способ оценки состояния больного ревматоидным артритом и эффективности его лечения | |
| UA110918C2 (uk) | Інгібітори протеїнфосфатази-1 та їх застосування | |
| UA50825U (ru) | Применение антагониста рецепторов интерлейкина-1 в качестве средства гипоурикемического действия | |
| UA106224C2 (en) | Crystalline insulin-conjugates |